294 related articles for article (PubMed ID: 32910655)
1. Identification of TNO155, an Allosteric SHP2 Inhibitor for the Treatment of Cancer.
LaMarche MJ; Acker M; Argintaru A; Bauer D; Boisclair J; Chan H; Chen CH; Chen YN; Chen Z; Deng Z; Dore M; Dunstan D; Fan J; Fekkes P; Firestone B; Fodor M; Garcia-Fortanet J; Fortin PD; Fridrich C; Giraldes J; Glick M; Grunenfelder D; Hao HX; Hentemann M; Ho S; Jouk A; Kang ZB; Karki R; Kato M; Keen N; Koenig R; LaBonte LR; Larrow J; Liu G; Liu S; Majumdar D; Mathieu S; Meyer MJ; Mohseni M; Ntaganda R; Palermo M; Perez L; Pu M; Ramsey T; Reilly J; Sarver P; Sellers WR; Sendzik M; Shultz MD; Slisz J; Slocum K; Smith T; Spence S; Stams T; Straub C; Tamez V; Toure BB; Towler C; Wang P; Wang H; Williams SL; Yang F; Yu B; Zhang JH; Zhu S
J Med Chem; 2020 Nov; 63(22):13578-13594. PubMed ID: 32910655
[TBL] [Abstract][Full Text] [Related]
2. Allosteric Inhibition of SHP2: Identification of a Potent, Selective, and Orally Efficacious Phosphatase Inhibitor.
Garcia Fortanet J; Chen CH; Chen YN; Chen Z; Deng Z; Firestone B; Fekkes P; Fodor M; Fortin PD; Fridrich C; Grunenfelder D; Ho S; Kang ZB; Karki R; Kato M; Keen N; LaBonte LR; Larrow J; Lenoir F; Liu G; Liu S; Lombardo F; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Ramsey T; Sellers WR; Shultz MD; Stams T; Towler C; Wang P; Williams SL; Zhang JH; LaMarche MJ
J Med Chem; 2016 Sep; 59(17):7773-82. PubMed ID: 27347692
[TBL] [Abstract][Full Text] [Related]
3. Allosteric Inhibitors of SHP2 with Therapeutic Potential for Cancer Treatment.
Xie J; Si X; Gu S; Wang M; Shen J; Li H; Shen J; Li D; Fang Y; Liu C; Zhu J
J Med Chem; 2017 Dec; 60(24):10205-10219. PubMed ID: 29155585
[TBL] [Abstract][Full Text] [Related]
4. Allosteric inhibition of SHP2 phosphatase inhibits cancers driven by receptor tyrosine kinases.
Chen YN; LaMarche MJ; Chan HM; Fekkes P; Garcia-Fortanet J; Acker MG; Antonakos B; Chen CH; Chen Z; Cooke VG; Dobson JR; Deng Z; Fei F; Firestone B; Fodor M; Fridrich C; Gao H; Grunenfelder D; Hao HX; Jacob J; Ho S; Hsiao K; Kang ZB; Karki R; Kato M; Larrow J; La Bonte LR; Lenoir F; Liu G; Liu S; Majumdar D; Meyer MJ; Palermo M; Perez L; Pu M; Price E; Quinn C; Shakya S; Shultz MD; Slisz J; Venkatesan K; Wang P; Warmuth M; Williams S; Yang G; Yuan J; Zhang JH; Zhu P; Ramsey T; Keen NJ; Sellers WR; Stams T; Fortin PD
Nature; 2016 Jul; 535(7610):148-52. PubMed ID: 27362227
[TBL] [Abstract][Full Text] [Related]
5. Selective inhibitors of the protein tyrosine phosphatase SHP2 block cellular motility and growth of cancer cells in vitro and in vivo.
Grosskopf S; Eckert C; Arkona C; Radetzki S; Böhm K; Heinemann U; Wolber G; von Kries JP; Birchmeier W; Rademann J
ChemMedChem; 2015 May; 10(5):815-26. PubMed ID: 25877780
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 6-[(3
Czako B; Sun Y; McAfoos T; Cross JB; Leonard PG; Burke JP; Carroll CL; Feng N; Harris AL; Jiang Y; Kang Z; Kovacs JJ; Mandal P; Meyers BA; Mseeh F; Parker CA; Yu SS; Williams CC; Wu Q; Di Francesco ME; Draetta G; Heffernan T; Marszalek JR; Kohl NE; Jones P
J Med Chem; 2021 Oct; 64(20):15141-15169. PubMed ID: 34643390
[TBL] [Abstract][Full Text] [Related]
7. 6-Amino-3-methylpyrimidinones as Potent, Selective, and Orally Efficacious SHP2 Inhibitors.
Sarver P; Acker M; Bagdanoff JT; Chen Z; Chen YN; Chan H; Firestone B; Fodor M; Fortanet J; Hao H; Hentemann M; Kato M; Koenig R; LaBonte LR; Liu G; Liu S; Liu C; McNeill E; Mohseni M; Sendzik M; Stams T; Spence S; Tamez V; Tichkule R; Towler C; Wang H; Wang P; Williams SL; Yu B; LaMarche MJ
J Med Chem; 2019 Feb; 62(4):1793-1802. PubMed ID: 30688459
[TBL] [Abstract][Full Text] [Related]
8. Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment.
Kerr DL; Haderk F; Bivona TG
Curr Opin Chem Biol; 2021 Jun; 62():1-12. PubMed ID: 33418513
[TBL] [Abstract][Full Text] [Related]
9. Combinations with Allosteric SHP2 Inhibitor TNO155 to Block Receptor Tyrosine Kinase Signaling.
Liu C; Lu H; Wang H; Loo A; Zhang X; Yang G; Kowal C; Delach S; Wang Y; Goldoni S; Hastings WD; Wong K; Gao H; Meyer MJ; Moody SE; LaMarche MJ; Engelman JA; Williams JA; Hammerman PS; Abrams TJ; Mohseni M; Caponigro G; Hao HX
Clin Cancer Res; 2021 Jan; 27(1):342-354. PubMed ID: 33046519
[TBL] [Abstract][Full Text] [Related]
10. PCC0208023, a potent SHP2 allosteric inhibitor, imparts an antitumor effect against KRAS mutant colorectal cancer.
Chen X; Zou F; Hu Z; Du G; Yu P; Wang W; Wang H; Ye L; Tian J
Toxicol Appl Pharmacol; 2020 Jul; 398():115019. PubMed ID: 32335126
[TBL] [Abstract][Full Text] [Related]
11. Dual Allosteric Inhibition of SHP2 Phosphatase.
Fodor M; Price E; Wang P; Lu H; Argintaru A; Chen Z; Glick M; Hao HX; Kato M; Koenig R; LaRochelle JR; Liu G; McNeill E; Majumdar D; Nishiguchi GA; Perez LB; Paris G; Quinn CM; Ramsey T; Sendzik M; Shultz MD; Williams SL; Stams T; Blacklow SC; Acker MG; LaMarche MJ
ACS Chem Biol; 2018 Mar; 13(3):647-656. PubMed ID: 29304282
[TBL] [Abstract][Full Text] [Related]
12. Optimization of Fused Bicyclic Allosteric SHP2 Inhibitors.
Bagdanoff JT; Chen Z; Acker M; Chen YN; Chan H; Dore M; Firestone B; Fodor M; Fortanet J; Hentemann M; Kato M; Koenig R; LaBonte LR; Liu S; Mohseni M; Ntaganda R; Sarver P; Smith T; Sendzik M; Stams T; Spence S; Towler C; Wang H; Wang P; Williams SL; LaMarche MJ
J Med Chem; 2019 Feb; 62(4):1781-1792. PubMed ID: 30688462
[TBL] [Abstract][Full Text] [Related]
13. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
Tang K; Jia YN; Yu B; Liu HM
Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
[TBL] [Abstract][Full Text] [Related]
14. Discovery of the SHP2 allosteric inhibitor 2-((3R,4R)-4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-5-(2,3-dichlorophenyl)-3-methylpyrrolo[2,1-f][1,2,4] triazin-4(3H)-one.
Luo Y; Li J; Zong Y; Sun M; Zheng W; Zhu J; Liu L; Liu B
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):398-404. PubMed ID: 36476046
[TBL] [Abstract][Full Text] [Related]
15. Recent Advances of SHP2 Inhibitors in Cancer Therapy: Current Development and Clinical Application.
Yuan X; Bu H; Zhou J; Yang CY; Zhang H
J Med Chem; 2020 Oct; 63(20):11368-11396. PubMed ID: 32460492
[TBL] [Abstract][Full Text] [Related]
16. Targeting a cryptic allosteric site for selective inhibition of the oncogenic protein tyrosine phosphatase Shp2.
Chio CM; Lim CS; Bishop AC
Biochemistry; 2015 Jan; 54(2):497-504. PubMed ID: 25519989
[TBL] [Abstract][Full Text] [Related]
17. Scaffold-based novel SHP2 allosteric inhibitors design using Receptor-Ligand pharmacophore model, virtual screening and molecular dynamics.
Jin WY; Ma Y; Li WY; Li HL; Wang RL
Comput Biol Chem; 2018 Apr; 73():179-188. PubMed ID: 29494926
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and biological evaluation of 2,5-diaryl-1,3,4-oxadiazole derivatives as novel Src homology 2 domain-containing protein tyrosine phosphatase 2 (SHP2) inhibitors.
Meng XD; Gao LX; Wang ZJ; Feng B; Zhang C; Satheeshkumar R; Li J; Zhu YL; Zhou YB; Wang WL
Bioorg Chem; 2021 Nov; 116():105384. PubMed ID: 34601294
[TBL] [Abstract][Full Text] [Related]
19. Small-Molecule Inhibitors of Shp2 Phosphatase as Potential Chemotherapeutic Agents for Glioblastoma: A Minireview.
Mitra R; Ayyannan SR
ChemMedChem; 2021 Mar; 16(5):777-787. PubMed ID: 33210828
[TBL] [Abstract][Full Text] [Related]
20. Probing the Dynamic Mechanism of Uncommon Allosteric Inhibitors Optimized to Enhance Drug Selectivity of SHP2 with Therapeutic Potential for Cancer Treatment.
Farrokhzadeh A; Akher FB; Soliman MES
Appl Biochem Biotechnol; 2019 May; 188(1):260-281. PubMed ID: 30430347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
